A型肉毒杆菌毒素用于面部上半部分。

Type A botulinum toxin in the upper aspect of the face.

作者信息

Hexsel Dóris, Dal'forno Taciana

机构信息

Department of Dermatology, School of Medicine, Universidade de Passo Fundo, Plinio Brasil Milano 476, 90520-000 Porto Alegre, RS, Brazil.

出版信息

Clin Dermatol. 2003 Nov-Dec;21(6):488-97. doi: 10.1016/j.clindermatol.2003.11.002.

DOI:10.1016/j.clindermatol.2003.11.002

PMID:14759582

Abstract

The use of botulinum toxin type A (BTX-A) for facial rejuvenation was first systematically developed by Carruthers and Carruthers on the upper aspect of the face. In the early 1990s, the first studies of the cosmetic use of BTX-A were published. BTX-A was only approved in 2002, however, by the U.S. Food and Drug Administration when extensive cosmetic studies were evaluated. The treatment of facial wrinkles with BTX-A has truly changed the concepts held by physicians regarding facial rejuvenation, mainly on the upper aspect of the face. It is one of the most common cosmetic procedures currently performed by physicians.

摘要

A型肉毒杆菌毒素（BTX-A）用于面部年轻化最初是由卡拉瑟斯夫妇在上半面部系统开发的。20世纪90年代初，关于BTX-A美容用途的首批研究发表。然而，直到2002年，美国食品药品监督管理局在评估了大量美容研究后才批准使用BTX-A。用BTX-A治疗面部皱纹确实改变了医生对面部年轻化的观念，主要是在上半面部。它是目前医生进行的最常见的美容手术之一。